

# IDEACON 2024

The 13<sup>th</sup> Annual Scientific Conference  
of the Integrated Diabetes and  
Endocrine Academy (IDEA)

**5<sup>th</sup> July, 2024** | **ITC Royal Bengal,**  
FRI SAT SUN **Kolkata**

SAVE THE  
DATES



**4<sup>th</sup> July, 2024**

Preconference Program  
Diabetes Educator Program  
& PGT Symposium

**5<sup>th</sup> July, 2024**

Inauguration  
Workshop  
Scientific Sessions  
Industry Symposium

**6<sup>th</sup> July, 2024**

Debate for Industry houses  
Scientific Sessions  
Vivekananda Oration  
Industry Symposium

**7<sup>th</sup> July, 2024**

Short Paper sessions  
Scientific Sessions  
Valediction



**Dr. Debasish Maji**  
Organising Chairperson



**Dr. Anirban Majumdar**  
Organising Secretary



**Dr. Kalyan Kumar  
Gangopadhyay**  
Scientific Chairperson



**Dr. J. J. Mukherjee**  
Co-Scientific Chairperson



**Dr. Samit Ghosal**  
Co Organising Secretary

# 4<sup>TH</sup> JULY (THURSDAY) 2024

## SYMPOSIUM FOR POST-GRADUATE STUDENTS : CASE BASED DISCUSSION

Time	Venue : HALL B (BSR 1 & BSR 2)	
07:00PM - 07:20PM	1) An 18 yrs old girl with primary amenorrhea	
07:25PM - 07:45PM	2) A 40 yrs old man with Lt thyroid nodule	
07:50PM - 08:10PM	3) A 29 old female with Hyperprolactinemia	
08:15PM - 08:35PM	4) A 25yrs old cricketer presenting with increasing lethargy and weight gain after a traumatic head injury	
08:40PM - 09:00PM	5) A 45 yrs old female with hypercalcemia	
09:00PM - 10:00PM	Dinner	

# 5<sup>TH</sup> JULY (FRIDAY) 2024

10:00AM-01:00PM	BSR 1	BSR 2	BSR 4	BSR5
10:00AM-10:45AM	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> Novo Nordisk</p> <p><b>Workshop topic:</b> Insulin regime in long distance air travel &amp; religious fasting</p>	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> BI</p> <p><b>Workshop topic:</b> ABCD of CGMS</p>	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Prescription of exercise regime in T2DM</p>	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> Mankind</p> <p><b>Workshop topic:</b> Nuances of insulin therapy - administration, insulin devices, storage</p>
10:45AM-11:30AM	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> topic:Managing subclinical hypothyroidism</p>	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Approach to cortisol insufficiency in inpatients</p>	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> TORRENT</p> <p><b>Workshop topic:</b> Evaluation of osteoporosis – Whom,when,how</p>	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Differential Diagnosis of hirsutism</p>
11:30AM-12:15PM	<p><b>Speaker:</b></p> <p><b>Sponsored by:</b> Sanofi</p> <p><b>Workshop topic:</b> Nuances of insulin therapy - administration, insulin devices, storage</p>	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> USV</p> <p><b>Workshop topic:</b> Insulin regime in long distance air travel &amp; religious fasting</p>	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> CIPLA</p> <p><b>Workshop topic:</b> ABCD of CGMS</p>	<p><b>Moderators:</b></p> <p><b>Sponsored by:</b> SUN</p> <p><b>Workshop topic:</b> Prescription of exercise regime in T2DM</p>
12:15PM-01:00PM	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Differential Diagnosis of hirsutism</p>	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Managing subclinical hypothyroidism</p>	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Approach to cortisol insufficiency in inpatients</p>	<p><b>Moderators:</b></p> <p><b>Workshop topic:</b> Evaluation of osteoporosis – Whom, when,how</p>

# Day 1: 5<sup>th</sup> July, 2024 (Friday) | Hall - A

<b>08:00AM – 09:00AM</b>	<b>Breakfast Symposium</b>
<b>09:00AM – 10:00AM</b>	<b>Inauguration</b>
<b>10:00AM – 01:00PM</b>	<b>Quiz for Industry participants</b>
<b>12:00PM – 03:00PM</b>	<b>No Lunch Break</b>
<b>01:00PM – 01:50PM</b>	<b>Bariatric Surgery, Nutrition and Diabetes Management</b>
<b>01:00PM – 01:20PM</b>	<b>Long term management of a person with T2DM post bariatric surgery</b>
<b>01:20PM – 01:40PM</b>	<b>Nutritional supplements in T2DM does it matter?</b>
<b>01:40PM – 01:50PM</b>	<b>Panel Discussion</b>
<b>01:50PM – 02:40PM</b>	<b>Controversies in Diabetes</b>
<b>01:50PM – 02:10PM</b>	<b>Pre pregnancy planning in T2 DM</b>
<b>02:10PM – 02:30PM</b>	<b>Non insulin therapy of hyperglycaemia in pregnancy</b>
<b>02:30PM – 02:40PM</b>	<b>Panel Discussion</b>
<b>02:40PM – 03:30PM</b>	<b>Debate 01: Best Gliptin: Session sponsor: MSD, Boehringer Ingelheim</b>
<b>02:40PM – 03:00PM</b>	<b>Best Gliptin - Sitagliptin</b>
<b>03:00PM – 03:20PM</b>	<b>Best Gliptin Linagliptin</b>
<b>03:20PM – 03:30PM</b>	<b>Panel Discussion</b>
<b>03:30PM – 04:20PM</b>	<b>Mental Health &amp; Diabetes: Session Sponsor: ALTEUS</b>
<b>03:30PM – 03:50PM</b>	<b>Recognizing depression in Diabetes</b>
<b>03:50PM – 04:10PM</b>	<b>Managing diabetes in patients with dementia</b>
<b>04:10PM – 04:20PM</b>	<b>Panel Discussion</b>
<b>04:20PM – 05:10PM</b>	<b>Kidney Health &amp; Diabetes: Session Sponsor: BAYER</b>
<b>04:20PM – 04:40PM</b>	<b>Preventing DKD beyond RAASB and SGLT2i</b>
<b>04:40PM – 05:00PM</b>	<b>Non diabetic kidney disease in T2DM</b>
<b>05:00PM – 05:10PM</b>	<b>Panel Discussion</b>
<b>05:10PM – 06:10PM</b>	<b>Industry Symposium : USV</b>
<b>05:10PM – 05:25PM</b>	<b>Topic:Modern SU + Metformin: Sustainable Kingpins of OADs</b>
<b>05:25PM – 05:40PM</b>	<b>SGLT2i as a First Line Antihyperglycemic Agent in of T2DM in the Indian Context</b>
<b>05:40PM – 05:55PM</b>	<b>Insulin Aspart: India's Journey Towards Biosimilar Excellence</b>
<b>05:55PM – 06:10PM</b>	<b>Panel Discussion</b>

# Day 1: 5<sup>th</sup> July, 2024 (Friday) | Hall - A

<b>06:10PM – 07:10PM</b>	<b>Industry Symposium : Torrent</b>
<b>06:10PM – 06:25PM</b>	<b>Met/SGLT2i/ DPP4i in the Indian context</b>
<b>06:25PM – 06:40PM</b>	<b>Tackling PP glucose with OHA beyond SU</b>
<b>06:40PM – 06:55PM</b>	<b>Positioning Imeglimin in current T2DM management</b>
<b>06:55PM – 07:10PM</b>	<b>Panel discussion</b>
<b>07:10PM – 08:10PM</b>	<b>Industry Symposium : Sanofi</b>
<b>07:00PM – 07:15PM</b>	<b>Combining efficacy with simplicity for T2D management</b>
<b>07:15PM – 07:30PM</b>	<b>Patient centric approach with basal insulin</b>
<b>07:30PM – 07:45PM</b>	<b>Paradigm shift in T2DM management with combination injectable of iGlarLixi</b>
<b>08:10PM – 09:10PM</b>	<b>Industry Symposium : BI</b>
<b>08:10PM – 08:30PM</b>	<b>Positioning SGLT2i+ DPP4i in T2DM management</b>
<b>08:30PM – 08:50PM</b>	<b>Renal-Metabolic Risk Reduction in T2DM</b>
<b>08:50PM – 09:10PM</b>	<b>Panel Discussion</b>

# Day 1: 5<sup>th</sup> July, 2024 (Friday) | Hall - B

<b>01:00PM – 01:50PM</b>	<b>Session Sponsor</b>
01:00PM – 01:20PM	Elevated serum triglycerides-to treat or not to treat-what is the evidence?
01:20PM – 01:40PM	What is the LDLC target in different risk groups? How best to achieve that target?
01:40PM – 01:50PM	Panel Discussion

<b>01:50PM – 02:40PM</b>	<b>Session Sponsor</b>
01:50PM – 02:10PM	Approach to a 22-yr-old female presenting with tetany and a corrected serum calcium value of 4.8 mg/dL
02:10PM – 02:30PM	Approach to a 22-yr-old ambulatory hypertensive male with a corrected serum calcium value of 13.5 mg/dL
02:30PM – 02:40PM	Panel Discussion

<b>02:40PM – 03:30PM</b>	<b>Session Sponsor</b>
02:40PM – 03:00PM	Approach to a 24-year-old female (BMI 28) with hirsutism (periods regular/no galactorrhea)
03:00PM – 03:20PM	Approach to a 28-year-old female (BMI 28) with irregular periods and a 9 AM follicular phase 17-OHP of 300 ng/dL
03:20PM – 03:30PM	Panel Discussion

<b>03:30PM – 04:20PM</b>	<b>Session Sponsor</b>
03:30PM – 03:50PM	What to assess and how to initiate THYROXINE replacement therapy in a 65-yr-old with FT4 0.2 ng/dL and TSH 128 uIU/mL
03:50PM – 04:10PM	Should we use T3+T4 in the management of primary hypothyroidism? An evidence based deliberation
04:10PM – 04:20PM	Panel Discussion

<b>04:20PM – 05:10PM</b>	<b>Session Sponsor</b>
04:20PM – 04:40PM	USG of a thyroid nodule: what's expected in a complete report? How to interpret it?
04:40PM – 05:00PM	FNAC of a thyroid nodule: what's expected in a complete report? How to interpret it?
05:00PM – 05:10PM	Panel Discussion

**Industry Symposium : Hall A**

# Day 2: 6<sup>th</sup> July, 2024 (Saturday) | Hall - A

<b>08:00AM – 09:00AM</b>	<b>BREAKFAST SYMPOSIUM: USV: Glycaemia management of hospitalized patients</b>
<b>09:00AM – 10:00AM</b>	<b>Session Sponsor</b>
<b>10:00AM – 10:20AM</b>	<b>Peripheral artery disease in DM in India</b>
<b>10:20AM – 10:40AM</b>	<b>Antimicrobial therapy of foot ulcer in T2DM in India</b>
<b>10:40AM – 10:50AM</b>	<b>Panel Discussion</b>
<b>10:00AM – 10:50AM</b>	<b>Debate 2:Which SGLT2i is the best? Session Sponsor: SUN, USV</b>
<b>10:00AM – 10:20AM</b>	<b>Empagliflozin has an edge over Dapagliflozin</b>
<b>10:20AM – 10:40AM</b>	<b>Dapagliflozin has an edge over Empagliflozin</b>
<b>10:40AM – 10:50AM</b>	<b>Panel Discussion</b>
<b>10:50AM – 12:00PM</b>	<b>Future of Diabetes:Session Sponsor:CIPLA</b>
<b>10:50AM – 11:10AM</b>	<b>Fast acting insulin analogues</b>
<b>11:10AM – 11:30AM</b>	<b>Incretin based therapy – the future</b>
<b>11:30AM – 11:50AM</b>	<b>Non insulin therapy of T1DM</b>
<b>11:50AM – 12:00PM</b>	<b>Panel Discussion</b>
<b>12:00PM – 03:00PM</b>	<b>NO LUNCH BREAK</b>
<b>12:00PM – 01:00PM</b>	<b>VIVEKANANDA ORATION</b>
<b>12:00PM – 12:20PM</b>	<b>Lifecourse evolution of diabetes</b>
<b>12:20PM – 01:00PM</b>	
<b>01:00PM – 01:50PM</b>	<b>Controversies in diabetes</b>
<b>01:00PM – 01:20 PM</b>	<b>Intermittent fasting in T2DM boon or bane</b>
<b>01:20PM – 01:40PM</b>	<b>Reversal of diabetes – myth or reality?</b>
<b>01:40PM – 01:50PM</b>	<b>Panel Discussion</b>
<b>01:50PM– 02:40PM</b>	<b>Debate 3:Best basal insulin: Session sponsor:NOVO + SANOFI</b>
<b>01:50PM – 02:10PM</b>	<b>Best basal Degludec</b>
<b>02:10PM – 02:30PM</b>	<b>Best basal Glargine U300</b>
<b>02:30PM – 02:40PM</b>	<b>Panel Discussion</b>
<b>02:40PM – 03:30PM</b>	<b>Debate 4: Best SU? Session Sponsor: TORRENT, MANKIND</b>
<b>02:40PM – 03:00PM</b>	<b>Best SU is Glimipiride</b>
<b>03:00PM – 03:20PM</b>	<b>Best SU is Gliclazide</b>
<b>03:20PM - 03:30PM</b>	<b>Panel Discussion</b>

# Day 2: 6<sup>th</sup> July, 2024 (Saturday) | Hall - A

<b>03:30PM - 04:20PM</b>	<b>Insulin resistance &amp; Glycaemic variability Session Sponsor: Dr Reddy`s</b>
03:30PM – 03:50PM	Approach to T2DM patients requiring > 100 insulin per day
03:50PM – 04:10PM	Clinical relevance of glycaemic variability in the Indian context
04:10PM – 04:20PM	Panel Discussion
<b>04:20PM – 05:10PM</b>	<b>Pitfalls in Biochemistry: Session Sponsor: Abbott healthcare</b>
04:20PM – 04:40PM	Pitfalls in interpreting HbA1C
04:40PM – 05:00PM	Pitfalls in interpreting biochemical tests in diabetes (K,lipid,fruct)
05:00PM – 05:10PM	Panel Discussion
<b>05:10PM - 06:10PM</b>	<b>Industry Symposium : MSD</b>
05:10PM - 05:30PM	Clinical Inertia and Reverse Clinical Inertia in T2DM management
05:30PM – 05:50PM	Less is more: Exploring the impact of DPP-4i as an add-on to Insulin in T2DM
05:50PM – 06:10PM	Panel Discussion
<b>06:10PM – 07:10PM</b>	<b>Industry Symposium : Sun</b>
06:10PM - 06:30PM	Intensification in T2DM
06:30PM – 06:50PM	Diabetic Comorbidities focus on HF and CKD
06:50PM – 07:10PM	Panel Discussion
<b>07:10PM - 08:10PM</b>	<b>Industry Symposium : Mankind</b>
07:10PM – 07:30PM	Position of 2nd generation Sulfonylureas in the Current era
07:30PM – 07:35PM	Q & A
07:35PM - 08:10PM	Panel Discussion : Topic: "Obesity as a common denominator for MAFLD, NASH & CVD in the 21st Century"
<b>08:10PM – 09:10PM</b>	<b>Industry Symposium : Novo</b>
08:10PM – 08:40PM	Clinical Case Seminar : Once daily insulins in clinical practice - Looking through the patient lens
08:40PM – 09:10PM	Exploring the Potential of Oral Semaglutide: A Conversation on Current Applications and Future Directions
<b>09:00PM - 10:00PM</b>	<b>DINNER</b>



# Day 2: 6<sup>th</sup> July, 2024 (Saturday) | Hall - B

<b>09:00AM – 09:50AM</b>	<b>Session Sponsor</b>
<b>09:00AM – 09:20AM</b>	<b>Approach to a 58-yr-old ambulatory person with T2DM and a serum sodium value of 126 mmol/L</b>
<b>09:20AM – 09:40AM</b>	<b>Endocrine causes of hypokalemia - case-based presentation to highlight differential diagnosis</b>
<b>09:40AM – 09:50AM</b>	<b>Panel Discussion</b>
<b>09:50AM – 10:40AM</b>	<b>Session Sponsor</b>
<b>09:50AM – 10:10AM</b>	<b>Physiology of glucose counterregulatory responses to hypoglycemia - what goes wrong during hypoglycemia unawareness</b>
<b>10:10AM – 10:30AM</b>	<b>Spontaneous hypoglycemia (non-diabetic person) - case based presentation to highlight differential diagnosis</b>
<b>10:30AM – 10:40AM</b>	<b>Panel Discussion</b>
<b>10:40AM – 12:00PM</b>	<b>Session Sponsor</b>
<b>10:40AM – 11:00PM</b>	<b>Weight loss achieved with GLP-1RAs - Brief mention of available clinical data with primary focus on mechanism(s) of action</b>
<b>11:00PM – 11:20AM</b>	<b>Weight loss achieved with GLP-1 + GIPRA - Brief mention of available clinical data with primary focus on mechanism(s) of action</b>
<b>11:20AM – 11:40AM</b>	<b>Weight loss achieved with GLP-1 + GIP + Glucagon RA - Brief mention of available clinical data with primary focus on mechanism(s) of action</b>
<b>11:40AM – 12:00PM</b>	<b>Panel Discussion</b>
<b>12:00PM – 03:00PM</b>	<b>NO LUNCH BREAK</b>
<b>12:00PM – 01:00PM</b>	<b>VIVEKANANDA ORATION : HALL A</b>
<b>01:00PM – 01:50PM</b>	<b>Session Sponsor</b>
<b>01:00PM – 01:20PM</b>	<b>37-year-old male with gynecomastia-algorithmic approach to arrive at the diagnosis</b>
<b>01:20PM – 01:40PM</b>	<b>74-year-old male with non-specific symptoms [9 AM T: 260 ng/dL (9 nmol/L) and LH 7 IU/L] - to treat or not-to-treat with T</b>
<b>01:40PM – 01:50PM</b>	<b>Panel Discussion</b>

# Day 2: 6<sup>th</sup> July, 2024 (Saturday) | Hall - B

<b>01:50PM – 02:40PM</b>	<b>Session Sponsor</b>
<b>01:50PM – 02:10PM</b>	<b>Anti-resorptive agents to treat osteoporosis (when, which one, and for how long)</b>
<b>02:10PM – 02:30PM</b>	<b>Anabolic agents to treat osteoporosis (when, which one, and for how long)</b>
<b>02:30PM – 02:40PM</b>	<b>Panel Discussion</b>
<b>02:40PM – 03:30PM</b>	<b>Session Sponsor</b>
<b>02:40PM – 03:00PM</b>	<b>Approach to a 32-year-old diabetic person with hypertension and hypokalemia - case(s) based presentation</b>
<b>03:00PM – 03:20PM</b>	<b>Approach to a 22-year-old male with a confirmed 4 cm retroperitoneal paraganglioma - case(s) based presentation</b>
<b>03:20PM – 03:30PM</b>	<b>Panel Discussion</b>
<b>03:30PM – 04:20PM</b>	<b>Session Sponsor</b>
<b>03:30PM – 03:50PM</b>	<b>25-year-old female (BMI 28 kg/m<sup>2</sup>) with irregular periods (no galactorrhea) and serum prolactin value of 46 ng/mL - when to treat?</b>
<b>03:50PM – 04:10PM</b>	<b>Suppression of HPA axis due to exogenous steroid intake-diagnosis, treatment, how &amp; when to discontinue replacement therapy</b>
<b>04:10PM – 04:20PM</b>	<b>Panel Discussion</b>
<b>04:20PM – 05:10PM</b>	<b>Session Sponsor</b>
<b>04:20PM – 04:40PM</b>	<b>Prevention and management of "hungry bone syndrome"</b>
<b>04:40PM – 05:00PM</b>	<b>Secondary hyperparathyroidism - definition, common causes, and management of SHPT due to CKD ("role of calcimimetics")</b>
<b>05:00PM – 05:10PM</b>	<b>Panel Discussion</b>

**Industry Symposium : Hall A**

# Day 3: 7<sup>th</sup> July, 2024 (Sunday) | Hall - A

<b>08:00AM – 09:00AM</b>	<b>Breakfast symposium - Zydus</b>
<b>09:00AM – 10:00AM</b>	<b>Short Paper Session</b>
<b>10:50AM – 11:40AM</b>	<b>All about SGLT2i: Session Sponsor: ASTRA</b>
<b>10:50AM - 11:10AM</b>	<b>Will incretin based therapy outrun SGLT2i in the future?</b>
<b>11:10 AM - 11:15AM</b>	<b>Q &amp; A</b>
<b>11:30AM – 11:40AM</b>	<b>Panel Discussion Topic: “Ask anything and everything about SGLT2i”</b>
<b>11:40AM – 12:30PM</b>	<b>Type 1 DM:Session Sponsor:LUPIN</b>
<b>11:40AM – 12:00PM</b>	<b>Guidelines and the real world of T1 DM management</b>
<b>12:00PM – 12:20PM</b>	<b>Type 1 Diabetes: The West Bengal Model</b>
<b>12:20PM –12:30PM</b>	<b>Panel Discussion</b>
<b>12:30PM – 01:20PM</b>	<b>Mixed Bag: Session Sponsor: INTAS</b>
<b>12:30PM – 12:50PM</b>	<b>T2 DM Diabetes in Young</b>
<b>12:50PM – 01:10PM</b>	<b>HTN management in T2DM: dos and don'ts</b>
<b>01:10PM – 01:20PM</b>	<b>Panel Discussion</b>
<b>01:20PM – 02:00PM</b>	<b>Valedictory Function</b>
<b>02:00PM – 03:00PM</b>	<b>LUNCH</b>

# Day 3: 7<sup>th</sup> July, 2024 (Sunday) | Hall - B

<b>10:00AM – 10:50AM</b>	<b>Session Sponsor</b>
10:00AM – 10:20AM	36-yr-old-female with PTC - post-total thyroidectomy, post 100 mCi RAI ablation - plan for long term follow-up
10:20AM – 10:40AM	Approach to a person with a 2 cm incidental pancreatic tail mass detected on Gallium dotatate PET-CT (SUVmax: 28)
10:40AM – 10:50AM	Panel Discussion
<b>10:50AM – 11:40AM</b>	<b>Session Sponsor</b>
10:50AM – 11:10AM	Approach to a 36-year-old ambulatory male presenting with complaints of polyuria (approximately 7-8 litres per day)
11:10AM – 11:30AM	Incidental detection of an empty sella - how to investigate and long-term follow-up plan if eupituitary
11:30AM – 11:40AM	Panel Discussion
<b>11:40AM – 12:30PM</b>	<b>Session Sponsor</b>
11:40AM – 12:00PM	Ambiguous genitalia in a baby with 46XX karyotype : a simplified algorithmic approach
12:00PM – 12:20PM	Idiopathic short stature (ISS) - when and how to diagnose? GH for all with ISS?
12:20PM – 12:30AM	Panel Discussion
<b>12:30PM – 01:20PM</b>	<b>Session Sponsor : ZYDUS</b>
12:30PM – 12:50PM	HRT in a 28 year-old female with premature ovarian failure
12:50PM – 01:10PM	ED - Focus on PDE5i - Which one to choose? Pros and cons of intermittent vs. chronic low dose administration
01:10PM – 01:20PM	Panel Discussion